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Patients with heterozygous inactivating
mutations in the gene encoding
glucokinase, which causes type 2
maturity-onset diabetes of the young
(MODY2), have mild fasting
hyperglycemia that usually remains
considerably stable during life and
requires only diabetic diet as treatment.
Atypical course of disease is uncommon.
An 11-year-old, prepubertal, Caucasian
overweight boy (BMI 22.5 kg/m2) with
gynecomastia/steatomastia and
diabetes was diagnosed on the basis of
an oral glucose tolerance test without
any typical symptoms (2-h blood
glucose 215 mg/dL). Insulin levels were
quite high (fasting 17.1 IU/mL, 2-h
114 IU/mL). Since 6 years of age he had
been treated for Asperger syndrome,
currently with risperidone. His family
history was positive for diabetes in the
previous three generations. At the time
of diabetes diagnosis, dyslipidemia with
elevated total cholesterol (212 mg/dL),
triglycerides (150 mg/dL), and LDL
cholesterol (133.1 mg/dL) was
observed. Diabetes autoantibodies
were significantly positive: islet antigen
2 antibodies (IA-2A) 46 units/mL
(N ,20), islet cell antibodies (ICA) 90
(N ,0), glutamic acid decarboxylase
antibodies (anti-GAD) 158.2 units/mL
(N ,9.1), and insulin autoantibodies
(IAA) 11.3% (N ,7). Heterozygosis for
GCG/GAG mutation in the glucokinase
gene was detected (data were from the
patient’s medical documentation from
another medical center).
The patient was admitted to our
department 2 years later with the goal
ofmodifying his treatment that included
insulin analogs, metformin, and
glimepiride, but not risperidone. HbA1c
had been fluctuating from 5.4–6.5%. His
current bodyweight was appropriate for
his height (27%). Puberty was Tanner
stage III. Lipid profile was normal.
Anti-GAD antibodies were negative 0.6
IU/mL. Five days after pharmacotherapy
discontinuation, a glucagon stimulation
test revealed high C-peptide levels
(baseline 3.1 ng/mL, 6 min after 8.9
ng/mL). In the following 2 years of
observation, the HbA1c had not
exceeded 6% (42 mmol/mol) on diet
treatment only. Notably, 3.5 years after
the first positive results, the patient’s
diabetes autoantibodies assessed by the
same person in the same certificated
laboratory were negative (IA-2A 2.07
units/mL, ICA 0, anti-GAD 3.5 units/mL).
According to the Diabetes Antibody
Standardization Program 2009/2nd Islet
Autoantibody Standardization Program
2012, the disease sensitivity of the
antibody was ICA 52–72.3%, GAD
antibodies 68–82%, IA-2A 66–70%, and
IAA 66%, while corresponding
specificities were ICA 76–93.3%, GAD
antibodies 75–94.4%, IA-2A 47.6–70%,
and IAA 49.6%.
There are no data in the literature
regarding significant high multiple islet
antibodies that disappear without the
development of type 1 diabetes.
However, some studies have shown that
the development of multiple islet
autoantibodies is a critical step in
pathogenesis and thus provides a robust
and early marker for risk of disease
progression (1). The data for prevalence
of positive diabetes autoantibodies in
MODY2 patients are scarce and vary
between publications (,1217%) (2,3).
The significance of the presence of
diabetes autoantibodies in these
patients remains unclear.
Some MODY2 patients display
peripheral insulin resistance that might
result from interactions between the
unbalanced glucose metabolism and
susceptibility of gene(s) to low insulin
sensitivity (4). In the present case,
risperidone could have prominent side
effects including weight gain and
hyperprolactinemia that resulted in the
development of gynecomastia and an
insulin-resistant state. It was reported
that metformin could be an effective
attenuator of risperidone-induced
insulin-resistant hyperglycemia and
dyslipidemia (5).
In conclusion, the positive diabetes
autoantibodies can be transient in
MODY2 patients and are not markers
of prediabetes. It is possible that
autoantibodies titers are aggravated
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by obesity or by other factors, such as
drugs.
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